Business Wire Industry News

Tuesday, March 26, 2019

Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key related findings as follows: 83% of the subjects (5 of 6) show stable disease (SD), including two tumor regressions 80% (4 of 5) with stable

Monday, March 25, 2019

Bioasis Technologies Inc. Announces Warrant Extension

GUILFORD, Conn.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has applied for approval from the TSX Venture Excha

Monday, March 25, 2019

Appili Therapeutics Announces Closing of $3.6 Million Special Warrant Private Placement and Filing of Preliminary Prospectus

HALIFAX, Nova Scotia--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24IMV&src=ctag" target="_blank"gt;$IMVlt;/agt; lt;a href="https://twitter.com/hashtag/AntibioticDeveloper?src=hash" target="_blank"gt;#AntibioticDeveloperlt;/agt;--Appili Therapeutics Inc. ("Appili" or the "Company") is pleased to announce the closing of its private placement offering (the "Brokered Offering") of special warrants (the "Special Warrants") for aggregate gross proceeds of $1,944,282, and with a concurrent non-brokered private placement offering (the “Non-Brokered Offering” and together with the Brokered Offering, the “Offering”) pursuant to which the Company raised aggregate gross proceeds of $1,642,532

Monday, March 25, 2019

IMV Inc. to Present at Two Upcoming Investor Conferences

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019. Details on each conference and presentation are as follows: •   Venue: Spring Investor Summit, being held April 1-2, 2019 • Date of Presentation: Monday, April 1 • Time: 8:30 a.m. ET • Location: JW Marrio

Monday, March 25, 2019

Titan Medical and Teleflex Incorporated Announce Collaboration for Development of Robotic Ligation Technology

TORONTO & WAYNE, Pa.--(BUSINESS WIRE)--Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”) and Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, announce a collaboration under which Teleflex’s market-leading polymer ligation technology will be integrated into Titan’

Friday, March 22, 2019

Titan Medical to Webcast Business Update Conference Call on March 28, 2019

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that management will webcast a conference call on Thursday, March 28 at 4:30 p.m. ET to provide a business update on the Company and its SPORT Surgical System. Speakers on the call will include David J. McNally, Chief Executiv

Thursday, March 21, 2019

IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today released its financial and operational results for year ending December 31, 2018. “IMV made significant advances in 2018,” said Frederic Ors, Chief Executive Officer. “Foundational changes, including shifting the name of the corporation to IMV and listing on Nasdaq, are enabling us to access to a larger pool of investors and allow us to better communicate our value prop

Thursday, March 21, 2019

Titan Medical Closes Public Offering

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce the closing of its previously announced public offering (the “Offering”) pursuant to an agency agreement dated March 18, 2019 between the Company and Bloom Burton Securities Inc. (the “Agent”). The Company closed

Thursday, March 21, 2019

Novanta to Present at Needham & Company 18th Annual Healthcare Conference on Tuesday, April 9, 2019

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the Needham & Company 18th Annual Healthcare Conference on Tuesday, April 9, 2019, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipmen

Thursday, March 21, 2019

Drug-Free Wireless Pain Relief Neurostimulator Changing Lives for Sufferers of Chronic Pain

BLAINVILLE, Quebec--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/BackPain?src=hash" target="_blank"gt;#BackPainlt;/agt;--Statistics Canada says six million people across the country suffer from chronic pain, meaning about 20 per cent of the population is affected. Everyone knows someone suffering from chronic pain and how debilitating it can be, but neurostimulation is changing many lives and offering a drug free alternative for pain management. While implantable neurostimulation has been approved by Health Canada for a decades, what’s different about Stimwave is the small siz

Tuesday, March 19, 2019

Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars. 2018 and Recent Highlights Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for claims which have the potential to cover voclosporin’s method of use and dosing protocol for lup